Optus Pharmaceutical Co. Ltd. (131030) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Optus Pharmaceutical Co. Ltd. (131030:KRX), powered by AI.

Current Price
₩6,100
P/E Ratio
9.5
Market Cap
107.6B
Sector
Healthcare
What is the Optus Pharmaceutical Co. Ltd. stock price forecast?

Optus Pharmaceutical Co. Ltd. is currently trading at ₩6,100. View real-time AI analysis on Alpha Lenz.

What is Optus Pharmaceutical Co. Ltd. insider trading activity?

View the latest insider trading data for Optus Pharmaceutical Co. Ltd. on Alpha Lenz.

What is Optus Pharmaceutical Co. Ltd.'s P/E ratio?

Optus Pharmaceutical Co. Ltd.'s P/E ratio is 9.5.

Optus Pharmaceutical Co. Ltd.

KRX · 131030
₩6,100-190(-3.02%)Market closedKRX regular session 09:00–15:30 KST
Ask about Optus Pharmaceutical Co. Ltd.'s future dividend policy...
Alpha Chat Insight

Optus Pharmaceutical Co. Ltd. trades at a P/E of 9.5 (undervalued) with modest ROE of 7.4%. 3Y revenue CAGR of 14.1% highlights clear growth momentum.

Ask for details

Company Overview

Optus Pharmaceutical Co. Ltd. is a company engaged in the development, manufacturing, and marketing of pharmaceutical products. Its primary function is to provide innovative and effective medications that cater to a wide range of medical needs. Optus Pharmaceutical focuses on both prescription drugs and over-the-counter pharmaceuticals, serving various therapeutic areas such as oncology, cardiovascular diseases, and infectious diseases. With a commitment to research and development, the company aims to introduce breakthrough drugs that enhance patient care and address unmet medical needs. Optus Pharmaceutical plays a significant role in the healthcare sector by collaborating with healthcare professionals, regulatory bodies, and research institutions. Its operations not only contribute to advancements in medical treatments but also have an impact on the pharmaceutical supply chain, affecting distribution channels worldwide. By consistently prioritizing quality and efficacy, Optus Pharmaceutical Co. Ltd. maintains its position as an important player in the global pharmaceutical industry.

CEO심상호
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

₩107,644,199,000Market Cap
₩87,161,378,620Revenue
17.65MShares Out
0Employees

Margins

55.28%Gross
17.86%EBITDA
10.18%Operating
12.68%Pre-Tax
13.03%Net

Valuation

9.48P/E
0.65P/B
1.24EV/Sales
5.65EV/EBITDA
-3.74P/FCF

Growth (CAGR)

14.11%Rev 3Yr
7.46%Rev 5Yr
19.06%Op Inc 3Yr
-10.56%Op Inc 5Yr
31.35%Net Inc 3Yr
-4.64%Net Inc 5Yr

Returns

6.35%ROA
7.36%ROE
6.22%ROIC

Financial Health

₩20,671,766,840Cash & Cash Equivalents
₩5,379,182,160Net Debt
15.79%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Optus Pharmaceutical Co. Ltd. (ticker: 131030) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $107.6B.

The current price is ₩6,100 with a P/E ratio of 9.48x and P/B of 0.65x.

ROE is 7.36% and operating margin is 10.18%. Annual revenue is $87.2B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Optus Pharmaceutical Co. Ltd. (131030) Stock Forecast 2026 ₩6,100 — Price, Financials & Analyst Targets | Alpha Lenz